INIS
patients
100%
hospitals
33%
tuberculosis
29%
therapy
26%
hiv
20%
doses
20%
drugs
20%
genes
19%
malaria
19%
plasmodium
19%
lungs
19%
genotype
15%
indonesia
14%
myeloid leukemia
13%
plasma
13%
diseases
13%
safety
13%
antibiotics
12%
phenotype
12%
concentration
12%
AIDS
11%
interactions
10%
mutations
10%
covid-19
10%
safety analysis
9%
surveys
9%
genetics
9%
pain
9%
cytochromes
9%
coronaries
9%
cost effectiveness analysis
9%
management
9%
aspirin
9%
pharmacotherapy
9%
children
9%
magnesium
9%
pharmacology
9%
maintenance
9%
leukemia
9%
coronaviruses
9%
corticosteroids
9%
reviews
9%
leprosy
9%
mice
9%
genetic variability
9%
methyl transferases
9%
risks
9%
control
8%
failures
8%
administration
6%
Keyphrases
Indonesian
30%
COVID-19
20%
Rifampicin
19%
Falciparum Malaria
19%
Database Study
19%
Leukemia Patients
18%
Chronic Myeloid Leukemia
17%
Efavirenz
16%
Major Molecular Response
15%
Adverse Effects
15%
AIDS/HIV
14%
Genotype
14%
Indonesia
14%
Tuberculosis
14%
Primaquine
12%
Retrospective Cohort Study
12%
Plasma Concentration
11%
Imatinib
11%
Chloroquine and Hydroxychloroquine
11%
Antiretroviral
11%
Tuberculosis Treatment
11%
Radical Cure
10%
Daily Dose
10%
Tuberculosis Infection
9%
HIV Viral Load
9%
Pain Pharmacology
9%
Corticosteroids
9%
Prospective Survey
9%
Clopidogrel
9%
Dual Antiplatelet Therapy
9%
Narrative Review
9%
Therapeutic Efficacy
9%
Cytochrome P450 2D6 (CYP2D6)
9%
Therapeutic Effectiveness
9%
Antiviral Treatment
9%
Safety Analysis
9%
Molecular Docking
9%
Pain Management
9%
Acute Coronary Syndrome
9%
Post-cesarean Section
9%
Leprosy Patients
9%
Clinical Pharmacology
9%
Angiotensin-converting Enzyme 2 Receptor
9%
Quinine
9%
Aspirin
9%
Cost-effectiveness Analysis
9%
Real-time Database
9%
Lung Tuberculosis
9%
Comorbid
9%
Hematotoxicity
9%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
20%
Rifampicin
19%
Plasmodium Vivax Malaria
19%
Imatinib
19%
Diseases
19%
Chloroquine
18%
Efavirenz
16%
Hydroxychloroquine
14%
Chronic Myeloid Leukemia
14%
Cohort Study
14%
Side Effect
12%
Primaquine
12%
Combination Therapy
11%
Tuberculosis
9%
Clopidogrel
9%
Acute Coronary Syndrome
9%
Acetylsalicylic Acid
9%
Antiplatelet
9%
CYP2D6
9%
Receptor
9%
Angiotensin Converting Enzyme 2
9%
Antivirus Agent
9%
Coronavirinae
9%
Clinical Pharmacology
9%
Tafenoquine
9%
Placebo
9%
Lung Tuberculosis
9%
Diabetes Mellitus
9%
Recurrence Risk
9%
Recurrent Disease
9%
Piperine
9%
Thiopurine Methyltransferase
7%
Cross-Sectional Study
6%
Adverse Event
6%
Cardiovascular Disease
6%
Infection
5%
SARS Coronavirus
5%
Lopinavir Plus Ritonavir
5%
Peptidase
5%